
Buyout firm Thoma Bravo has expressed interest in acquiring Twitter, reportedly considering presenting the social media company with an offer that rivals multi-billionaire Elon Musk’s $43 billion bid.
As Reuters reported Friday (April 15), citing sources familiar with the matter, Thoma Bravo, a private equity firm, has told Twitter it was exploring making the bid. The company had more than $103 billion in assets under management at the end of 2021.
Related: Elon Musk Offers To Buy Twitter
The Reuters report says it’s not clear how much Thoma Bravo would be prepared to offer. It’s also not certain that a bid will even come to pass.
Also on Friday, Twitter’s board executed a so-called “poison pill” measure. This is a shareholders’ rights plan that gives Twitter shareholders — aside from Musk — the ability to acquire more shares of the company at a lower price, thus diluting Musk’s stake.
“The Rights Plan will reduce the likelihood that any entity, person or group gains control of Twitter through open market accumulation without paying all shareholders an appropriate control premium or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of shareholders,” Twitter said in a news release.
Musk announced his intention to purchase Twitter in a filing with the U.S. Securities and Exchange Commission, saying he would purchase the company for $54.20 per share in cash, about 54% premium over the Jan. 28 closing price and a value of about $43 billion, calling the bid “best and final.”
The billionaire and Tesla CEO said he wants to make Twitter a private company and turn it into a platform for “free speech,” according to a filing. The move follows Musk’s purchase of 9% of the company last week and his decision to decline a seat on its board.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas